Edition:
United Kingdom

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

11.21USD
23 Apr 2018
Change (% chg)

$-0.21 (-1.84%)
Prev Close
$11.42
Open
$11.46
Day's High
$11.48
Day's Low
$11.06
Volume
115,425
Avg. Vol
191,070
52-wk High
$15.06
52-wk Low
$5.32

Chart for

About

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid,... (more)

Overall

Beta: --
Market Cap(Mil.): $364.45
Shares Outstanding(Mil.): 31.91
Dividend: --
Yield (%): --

Financials

  CLSD.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -2.33 -- --
ROI: -110.88 -0.74 13.21
ROE: -126.73 -2.80 15.01

BRIEF-Clearside Biomedical Reports Q4 Loss Per Share $0.65

* CLEARSIDE BIOMEDICAL ANNOUNCES FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

14 Mar 2018

BRIEF-Clearside Proposes Public Offering Of $75 Mln Of Shares

* CLEARSIDE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

06 Mar 2018

BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion

* CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION

06 Mar 2018

UPDATE 2-Clearside Biomedical's shares surge as eye drug succeeds in trial

* Shares surge 50 pct (Adds comments from analyst and conference call, background; updates share movement)

05 Mar 2018

Clearside Biomedical's eye treatment succeeds study, shares surge

Drug developer Clearside Biomedical Inc said on Monday its treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study, sending its shares surging 54.1 percent in premarket trading.

05 Mar 2018

Clearside Biomedical's eye treatment succeeds late-stage study

March 5 Clearside Biomedical Inc said on Monday its treatment for fluid build-up in the eye had met the main goal of a late-stage study.

05 Mar 2018

BRIEF-Clearside Biomedical Q3 loss per share $0.72

* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update

08 Nov 2017

BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema

24 Oct 2017

Competitors

Earnings vs. Estimates